Ixazomib citrate [MLN9708]

Overview
Catalog #	bs-75560c-1mg
Product Name	Ixazomib citrate [MLN9708]
Specifications
Storage Buffer	Solid
Storage Condition	Stable for 2 years after receipt when stored at -20°C.
Target
Product Information	CAS Number: 1239908-20-3 Molecular formula: C20H23BCl2N2O9 Molecular weight: 517.1 Purity: >95% (1H-NMR) Appearance: White solid. Solubility: Soluble in DMSO (5mg/ml) or DMF (5mg/ml). Poorly soluble in aqueous buffers. InChiKey: MBOMYENWWXQSNW-AWEZNQCLSA-N SMILES: CC(C)C[C@H](NC(CNC(C1=C(Cl)C=CC(Cl)=C1)=O)=O)B(O2)OC(CC(O)=O)(CC(O)=O)C2=O
Description	Potent selective and reversible proteasome inhibitor (all proteolytic subunits). Targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50=3.4nM). Cross-reacts and inhibits the trypsin-like beta2 subunit (IC50=3.5µM) and the caspase-like/peptidyl-glutamyl peptide-hydrolyzing (PGPH) beta1 subunit (IC50=0.03µM). Anticancer compound effective in cell-based assays, in xenografts and against multiple myeloma in vivo. In vitro, induces cell cycle arrest and apoptosis in human cancer cell lines including multiple myeloma. Prodrug that rapidly hydrolyzes to MLN2238 (Prod. No. bs-75559C). Exhibits improved pharmacodynamics and antitumor activity compared to bortezomib (Prod. No. bs-75509C) in various B cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models.